Koppers (KOP) Stock Forecast & Price Target

Koppers Holdings Inc. demonstrated substantial financial growth, with adjusted EBITDA surging by 78.1% to $5.04 million and gross profit rising by 43.7% to $12.2 million, underscoring effective operating leverage and enhanced gross margins. The company experienced a remarkable total revenue growth of 41.6%, bolstered by significant increases in both Plasma revenue and Pharma patient affordability revenue, with the latter soaring by 141.9% to $7.9 million. Koppers is also anticipating ongoing revenue expansion, particularly within its Performance Chemicals segment, projecting a growth of 11% in 2026 driven by market share gains across residential and industrial product categories.

Koppers Holdings Inc. experienced a significant decline in consolidated sales of 9.3% in Q4/25, resulting in total annual sales plummeting 10% to $1.9 billion compared to the previous year. The performance of the Railroad and Utility Products and Services (RUPS) segment also showed negative trends, with net sales down 3.2% year-over-year, further indicating challenges in revenue generation. Additionally, revised expectations for adjusted EBITDA reflect a notable reduction from $28 million to $17.5 million, highlighting concerns over declining market demand and potential difficulties in capturing growth from operational initiatives.